Skip to content
Brand AI

Keytruda

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2017

    Merck settles PD-1 patent litigation with BMS and Ono

    Settlement

    Merck agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625 million and royalties on Keytruda sales to settle patent infringement litigation concerning PD-1 inhibitors. The agreement provided for dismissal of the patent litigation filed against Merck.

    Source excerpt

    • The US drugmaker has agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625m to settle the patent infringement litigation – focusing on intellectual property in the area of PD-1 inhibitors – and will also pay a 6.5% royalty on sales of Keytruda (pembrolizumab) through to December 2023.
    • Phil Taylor 23rd January 2017
    Source